Приказ основних података о документу

dc.creatorOdalović, Marina
dc.creatorVezmar-Kovačević, Sandra
dc.creatorIlić, Katarina
dc.creatorSabo, Ana
dc.creatorTasić, Ljiljana
dc.date.accessioned2019-09-02T11:27:21Z
dc.date.available2019-09-02T11:27:21Z
dc.date.issued2012
dc.identifier.issn2210-7703
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/1636
dc.description.abstractBackground Observation of drug use patterns during pregnancy is necessary for the recognition of potential bad practices and improvement of safe drug use in pregnancy. Objective To investigate prescription and over the counter drug use among Serbian women in the 6 months before pregnancy and in the first 6 months of pregnancy, and to evaluate the drugs used according to the risk to a fetus. Setting Six maternity care units and five community pharmacies Method A multi-center study was performed in Serbia during the period from March 2009-March 2010. A self-reporting questionnaire was used as a data source. Food and Drug Administration (FDA) risk classification system was used to determine the risk of used drugs for the fetus. Differences between subgroups were assessed using McNemar's test on paired proportions. Main outcome measure Proportion of women exposed to drugs or class of drugs. Results The overall drug exposure was higher in pregnancy (34.7 %) than before pregnancy (29.9 %), p > 0.05, in the cohort of 311 pregnant women. A significantly greater prescription drug use, 19.0 versus 27.3 % of women, p lt 0.05, and less selfmedication with over the counter drugs in pregnancy, 15.1 versus 8.7 %, p lt 0.05, were observed. Commonly used drugs were musculoskeletal drugs, analgesics/antipyretics and respiratory system drugs before pregnancy (13.8, 12.5, and 6.4 % of women, respectively), and progestogens, analgesics/antipyretics, and antibiotics for the systemic use in pregnancy (9.0, 7.7, and 7.4 %, respectively). A greater exposure to drugs belonging to the FDA risk category A (3.9 vs. 60.8 %, p lt 0.05), B (18.0 vs. 19.6 %, p > 0.05), C (10.0 vs. 10.3 %, p > 0.05) and D (2.9 vs. 10.9 %, p lt 0.05), as well as less exposure to drugs belonging to category X (0.3 vs. 0 %, p > 0.05) were observed in pregnancy. Folic acid was used by 60.8 % of women in pregnancy, and by only 3.9 % before pregnancy. Conclusion Besides higher overall drug use in pregnancy than before pregnancy, particularly the use of progestogens, and, subsequently, D category drugs, less selfmedication with over the counter drugs was observed in pregnancy. Insufficient use of folic acid before pregnancy requires public health service activities.en
dc.publisherSpringer, Dordrecht
dc.relationinfo:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41012/RS//
dc.rightsrestrictedAccess
dc.sourceInternational Journal of Clinical Pharmacy
dc.subjectDrug useen
dc.subjectFDA pregnancy risk classificationen
dc.subjectOTC medicationen
dc.subjectPregnancyen
dc.subjectSerbiaen
dc.titleDrug use before and during pregnancy in Serbiaen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractИлић, Катарина; Тасић, Љиљана; Сабо, Aна; Одаловић, Марина; Везмар-Ковачевић, Сандра;
dc.citation.volume34
dc.citation.issue5
dc.citation.spage719
dc.citation.epage727
dc.citation.other34(5): 719-727
dc.citation.rankM23
dc.identifier.wos000309676500009
dc.identifier.doi10.1007/s11096-012-9665-8
dc.identifier.pmid22744842
dc.identifier.scopus2-s2.0-84867400463
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу